Want to see SYK full AI Analyst Report?
SYK Stock Chart & Stats
$343.32
$6.61(1.86%)
At close: 4:00 PM EST
$343.32
$6.61(1.86%)
Day’s Range― - ―
52-Week Range$281.00 - $404.87
Previous CloseN/A
Volume378.36K
Average Volume (3M)2.56M
Market Cap
$125.40B
Enterprise Value$127.80B
Total Cash (Recent Filing)$2.96B
Total Debt (Recent Filing)$15.23B
Price to Earnings (P/E)37.9
Beta0.55
Next Earnings
Jul 30, 2026EPS Estimate
3.49Next Dividend Ex-DateN/A
Dividend Yield0.95%
Share Statistics
EPS (TTM)8.73
Shares Outstanding383,360,750
10 Day Avg. Volume2,613,085
30 Day Avg. Volume2,560,061
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue5.06
Enterprise Value/Gross Profit7.94
Enterprise Value/Ebitda20.74
Forecast
1Y Price Target
$384.53Price Target Upside12.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)14.98
Revenue Forecast (FY)$27.27B
Bulls Say, Bears Say
Bulls Say
Scale & Gross MarginsStryker's materially larger revenue base and sustained ~60–64% gross margins indicate durable scale and pricing power in hospitals and surgical settings. Scale supports R&D, distribution and marketing investments that reinforce competitive position and defend margins over the medium term.
Cash Generation & FCF ConversionRobust and improving cash generation with multi‑billion FCF provides lasting flexibility to fund acquisitions, product rollouts, dividends and debt paydown. Consistent FCF supports strategic investment without depending on equity markets, strengthening long‑term financial durability.
Robotics & Product MomentumStrong robotic adoption and new product rollouts (Mako, RPS handheld, Mako 4) create an expanding installed base and recurring consumable/service revenue. Coupled with the Ortho Tech reorganization, this should accelerate commercialization and deepen durable differentiation in orthopaedics.
Bears Say
Margin CompressionA sustained decline from peak net margins signals structural cost pressures (tariffs, absorption from disruptions, higher interest) that can erode profitability even as revenue grows. If cost headwinds persist, margin recovery may be slow and constrain cash flow expansion.
High Absolute Debt & Interest SensitivityWhile leverage has improved, a sizable absolute debt stock makes Stryker exposed to refinancing and rising interest costs, reducing financial flexibility. Higher interest expense can pressure net income and free cash flow, limiting speed of deleveraging or capital deployment during rate shocks.
Operational Risk: Cyber IncidentA major cyber event that disrupted manufacturing, shipments and revenue recognition exposes persistent operational and reputational vulnerabilities. Recovery costs, lost procedures and potential customer trust erosion can have lasting effects on hospital relationships and recurring revenue if not fully mitigated.
SYK FAQ
What was Stryker Corp’s price range in the past 12 months?
Stryker Corp lowest stock price was $281.00 and its highest was $404.87 in the past 12 months.
What is Stryker Corp’s market cap?
Stryker Corp’s market cap is $125.40B.
When is Stryker Corp’s upcoming earnings report date?
Stryker Corp’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Stryker Corp’s earnings last quarter?
Stryker Corp released its earnings results on Apr 30, 2026. The company reported $2.6 earnings per share for the quarter, missing the consensus estimate of $2.981 by -$0.381.
Is Stryker Corp overvalued?
According to Wall Street analysts Stryker Corp’s price is currently Undervalued.
Does Stryker Corp pay dividends?
Stryker Corp pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 0.95%. See more information on Stryker Corp dividends here
What is Stryker Corp’s EPS estimate?
Stryker Corp’s EPS estimate is 3.49.
How many shares outstanding does Stryker Corp have?
Stryker Corp has 383,360,750 shares outstanding.
What happened to Stryker Corp’s price movement after its last earnings report?
Stryker Corp reported an EPS of $2.6 in its last earnings report, missing expectations of $2.981. Following the earnings report the stock price went down -6.474%.
Which hedge fund is a major shareholder of Stryker Corp?
Currently, no hedge funds are holding shares in SYK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stryker Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$384.53 (12.00% Upside)
$384.53 (12.00% Upside)
Blogger Sentiment
Bullish
SYK Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $99.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.71%
12-Months-Change
Fundamentals
Return on Equity
15.10%
Trailing 12-Months
Asset Growth
0.62%
Trailing 12-Months
Company Description
Stryker Corp
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
SYK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call mixed a significant near-term operational setback—the late-quarter cyber incident that materially distorted Q1 results, pressured margins and reduced EPS—with several strong positives: rapid operational recovery, record Mako installations and robust robotic momentum, continued healthy underlying demand, strategic reorganization (Ortho Tech), active M&A (AVS) and maintained full-year guidance (organic sales growth 8.0%–9.5%, adjusted EPS $14.90–$15.10). Management expects most lost Q1 sales to be realized through the rest of the year, with catch-up skewed to the back half, and emphasized customer/employee support and successful recovery efforts.View all SYK earnings summariesSYK Net sales Breakdown
62.30% MedSurg and Neurotechnology
37.70% Orthopaedics and Spine

SYK Stock 12 Month Forecast
Average Price Target
$384.53
▲(12.00% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Zimmer Biomet Holdings
―
Ownership Overview
4.00% Insiders
19.34% Mutual Funds
0.57% Other Institutional Investors
55.74% Public Companies and Individual Investors









